Literature DB >> 10984123

Heterocyclic modifications of oligonucleotides and antisense technology.

P Herdewijn1.   

Abstract

Modification of the heterocyclic moiety of oligonucleotides has led to the discovery of potent antisense compounds. This review describes the physicochemical factors that are responsible for duplex stabilization through base modification. A summary is given of the different heterocyclic modifications that can be used to beneficially influence this duplex stability. The biologic activity of base-modified oligonucleotides is described, and the different factors that are important for obtaining in vivo antisense activity with heterocyclic-modified oligonucleotides are summarized.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10984123     DOI： 10.1089/108729000421475

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN： 1087-2906


  8 in total

1.  Diversity-oriented, one-pot, multi-component synthesis of substituted uracil derivatives.

Authors:  Yogesh Y Pedgaonkar; Mariam S Degani; Radhakrishnan P Iyer
Journal:  Mol Divers       Date:  2010-08-20       Impact factor: 2.943

2.  Improved hybridisation potential of oligonucleotides comprising O-methylated anhydrohexitol nucleoside congeners.

Authors:  A Van Aerschot; M Meldgaard; G Schepers; F Volders; J Rozenski; R Busson; P Herdewijn
Journal:  Nucleic Acids Res       Date:  2001-10-15       Impact factor: 16.971

3.  Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides.

Authors:  Hyunmin Kang; Michael H Fisher; Dong Xu; Yuko J Miyamoto; Arnaud Marchand; Arthur Van Aerschot; Piet Herdewijn; Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2004-08-17       Impact factor: 16.971

4.  Role of pK(a) of nucleobases in the origins of chemical evolution.

Authors:  Ramanarayanan Krishnamurthy
Journal:  Acc Chem Res       Date:  2012-04-26       Impact factor: 22.384

5.  Insights into the DNA stabilizing contributions of a bicyclic cytosine analogue: crystal structures of DNA duplexes containing 7,8-dihydropyrido [2,3-d]pyrimidin-2-one.

Authors:  Ella Czarina Magat Juan; Satoru Shimizu; Xiao Ma; Taizo Kurose; Tsuyoshi Haraguchi; Fang Zhang; Masaru Tsunoda; Akihiro Ohkubo; Mitsuo Sekine; Takayuki Shibata; Christopher L Millington; David M Williams; Akio Takénaka
Journal:  Nucleic Acids Res       Date:  2010-06-16       Impact factor: 16.971

Review 6.  Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles.

Authors:  Jeremy P Bost; Hanna Barriga; Margaret N Holme; Audrey Gallud; Marco Maugeri; Dhanu Gupta; Taavi Lehto; Hadi Valadi; Elin K Esbjörner; Molly M Stevens; Samir El-Andaloussi
Journal:  ACS Nano       Date:  2021-09-10       Impact factor: 15.881

7.  RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications.

Authors:  Margit Mutso; Andrei Nikonov; Arno Pihlak; Eva Žusinaite; Liane Viru; Anastasia Selyutina; Tõnu Reintamm; Merike Kelve; Mart Saarma; Mati Karelson; Andres Merits
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

Review 8.  Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases.

Authors:  Jacob Helm; Ludger Schöls; Stefan Hauser
Journal:  Pharmaceutics       Date:  2022-08-16       Impact factor: 6.525
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.